Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors by Maddalena Centanni, Lena E. Friberg

Connect to this object online.

Bayesian forecasting of tumor size metrics and overall survival by Sreenath M. Krishnan, Lena E. Friberg

Connect to this object online.

Dr. Hartmut Derendorf, PhD, a world‐renowned expert in pharmacokinetics and pharmacometrics (1953-2020) by Vikram Sinha, Lena E. Friberg, Ping Zhao

Connect to this object online.

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models by Eman I. K. Ibrahim, Mats O. Karlsson, Lena E. Friberg

Connect to this object online.

Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies by Anders Thorsted, Anh Duc Pham, Lena E. Friberg, Elisabet I. Nielsen

Connect to this object online.

Multistate modeling for survival analysis in critically ill patients treated with meropenem by Yaru Peng, Iris K. Minichmayr, Han Liu, Feifan Xie, Lena E. Friberg

Connect to this object online.

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors by Maddalena Centanni, Abel Thijs, Ingrid Desar, Mats O. Karlsson, Lena E. Friberg

Connect to this object online.

Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against <em>Pseudomonas aeruginosa</em> to Clinical Settings by Iris K. Minichmayr, Suzanne Kappetein, Margreke J. E. Brill, Lena E. Friberg

Connect to this object online.

Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel by Sreenath M. Krishnan, Sofiene S. Laarif, Brendan C. Bender, Angelica L. Quartino, Lena E. Friberg

Connect to this object online.

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel by Sreenath M. Krishnan, Lena E. Friberg, René Bruno, Ulrich Beyer, Jin Y. Jin, Mats O. Karlsson

Connect to this object online.

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time by Ida Netterberg, René Bruno, Ya‐Chi Chen, Helen Winter, Chi‐Chung Li, Jin Y. Jin, Lena E. Friberg

Connect to this object online.

Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessmen... by Robin J. Svensson, Qing Xi Ooi, Lena E. Friberg, Narendra Maharaj, Pramod Kumar Reddy, Luis López‐Lázaro, Emma Hansson

Connect to this object online.

Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL by Javier Sanchez, Javier Sanchez, Christina Claus, Christine McIntyre, Tamara Tanos, Axel Boehnke, Lena E. Friberg, Siv Jönsson, Nicolas Frances

Connect to this object online.

CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision by Karen Rowland Yeo, Stefanie Hennig, Sriram Krishnaswami, Natasha Strydom, Vivaswath S. Ayyar, Jonathan French, Vikram Sinha, Eric Sobie, Ping Zhao, Lena E. Friberg, France Mentré

Connect to this object online.

A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer by Han Liu, Ana‐Marija Milenković‐Grišić, Sreenath M. Krishnan, Siv Jönsson, Lena E. Friberg, Pascal Girard, Karthik Venkatakrishnan, Yulia Vugmeyster, Akash Khandelwal, Mats O. Karlsson

Connect to this object online.

A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology by Javier Sánchez, Christina Claus, Rosmarie Albrecht, Brenda C. Gaillard, Joana Marinho, Christine McIntyre, Tamara Tanos, Axel Boehnke, Lena E. Friberg, Siv Jönsson, Nicolas Frances

Connect to this object online.

Integration of individual preclinical and clinical anti‐infective PKPD data to predict clinical study outcomes by Vincent Aranzana‐Climent, Wisse van Os, Amir Nutman, Jonathan Lellouche, Yael Dishon‐Benattar, Nadya Rakovitsky, George L. Daikos, Anna Skiada, Ioannis Pavleas, Emanuele Durante‐Mangoni, Ursula Theuretzbacher, Mical Paul, Yehuda Carmeli, Lena E. Friberg

Connect to this object online.

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib by Anyue Yin, G. D. Marijn Veerman, Johan G. C. vanHasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes

Connect to this object online.

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer by Ruben A. G. van Eerden, Leni van Doorn, Femke M. de Man, Niels Heersche, Michail Doukas, Thierry P. P. van den Bosch, Esther Oomen-de Hoop, Peter de Bruijn, Sander Bins, Eman Ibrahim, Suzan Nikkessen, Lena E. Friberg, Stijn L. W. Koolen, Stijn L. W. Koolen, Manon C. W. Spaander, Ron H. J. Mathijssen

Connect to this object online.